Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohortAndrea Serafin, Andrea Visentin, Alessandro Sanna et al.|Blood Advances|2025Cited by 3
Role of chemotherapy in the treatment of chronic lymphocytic leukemia in the era of targeted therapies in Italy. A Campus CLL network reportLaura Ballotta, Roberto Marasca, Monica Maccaferri et al.|Hematological Oncology|2022Cited by 2
Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)Enrica Antonia Martino, Federico Vozzella, Raffaella Pasquale et al.|Blood|2024Cited by 0
Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive studyAndrea Visentin, Giuseppe Petruzzellis, Thomas Chatzikonstantinou et al.|Blood|2025Cited by 0